Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $54.64

AnaptysBio, Inc. (NASDAQ:ANAB) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $54.64.

ANAB has been the topic of several research reports. Truist Financial raised their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. UBS Group raised their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Guggenheim raised their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. The trade was a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares of the company’s stock, valued at $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio in the first quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in AnaptysBio in the 1st quarter valued at about $265,000. Acadian Asset Management LLC acquired a new position in shares of AnaptysBio in the 1st quarter valued at $420,000. Platinum Investment Management Ltd. acquired a new stake in shares of AnaptysBio during the 1st quarter worth about $1,490,000. Finally, StemPoint Capital LP raised its holdings in AnaptysBio by 499.0% in the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after buying an additional 224,548 shares during the period.

AnaptysBio Stock Up 5.2 %

NASDAQ:ANAB opened at $22.27 on Friday. The company’s 50 day moving average price is $29.42 and its 200-day moving average price is $29.69. AnaptysBio has a 52 week low of $13.36 and a 52 week high of $41.31. The stock has a market cap of $677.68 million, a price-to-earnings ratio of -3.66 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, sell-side analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.